New gene therapy for multiple myeloma enters clinical trial
The first patient has been dosed in a Phase 1 clinical trial that’s testing a gene therapy for people with recurring or treatment-resistant multiple…
Steve Bryson, PhD, science writer—
Articles by Steve Bryson
Xspray seeking FDA approval for oral CML treatment XS003
Xspray Pharma has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for its oral therapy XS003 (nilotinib) for the…
Hemispherian gets FDA green-light for glioblastoma trial of GLIX1
The U.S. Food and Drug Administration (FDA) will allow Hemispherian to test its first-in-class experimental therapy for glioblastoma in a Phase 1 clinical trial.
2 of 3 ovarian cancer patients in study respond to SON-1010 combo
Sonnet Biotherapeutics is now testing its immunotherapy SON-1010, in combination with the immune checkpoint inhibitor Tecentriq (atezolizumab), in more patients — and soon, at…
Immune cells in blood may be glioma biomarkers: Study
A study found that analyzing levels of immune cells and related molecules in the bloodstream of people with glioma can accurately distinguish between different…
FDA OKs label changes to boost CAR T-cell therapy use for cancer
The U.S. Food and Drug Administration (FDA) has approved label updates for two Bristol Myers Squibb (BMS) CAR T-cell therapies, both for the treatment…
Oral Inqovi, venetoclax for acute myeloid leukemia to be reviewed
The U.S. Food and Drug Administration (FDA) has agreed to review an application for oral Inqovi (decitabine and cedazuridine) in combination with oral venetoclax for…
Cell therapy anito-cel extends treatment-resistant RRMM survival
Nearly all the people with relapsed or refractory multiple myeloma (RRMM) who took part in a Phase 2 clinical trial responded to the cell…
Exportin-1 function may explain blood cancer treatment side effects
Exportin-1, a therapeutic target for nuclear export inhibitors — a class of drugs used to treat blood cancers including multiple myeloma and leukemia…
Orca-T outperforms standard stem cell transplant for blood cell cancer
Orca-T, Orca Bio‘s investigational allogeneic stem cell transplant for treating blood cell cancers, more than doubled the rate of survival free from moderate…
